The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates if approved.
All entries for: Oncology
March 12, 2026
Tonix Pharmaceuticals Holding Corp.
Neutral Outlook
Berkeley, CA
51-200 employees
There is no assurance that federal or state health care reform will not adversely affect our future business and financial results, and we cannot predict how future federal or state legislative, judicial or administrative changes relating to healthcare policy will affect our business.
Disease Area: Immune Diseases, Infectious Diseases, Neurological Diseases, Oncology, Psychiatry, Rare Disease
Drug Type: Biologic, Small Molecule
March 12, 2026
Lisata Therapeutics
Neutral Outlook
Basking Ridge, NJ
1-50 employees
Ultimately, the IRA’s impact on the biopharmaceutical industry in the United States remains uncertain, in part because of multiple ongoing lawsuits against CMS brought by large pharmaceutical companies and other stakeholders
Disease Area: Oncology, Psychiatry
Drug Type: Small Molecule
March 12, 2026
Theriva Biologics, Inc.
Negative Outlook
Rockville, MD
1-50 employees
Although full economic effect of the IRA on our business and the pharmaceutical industry in general is unknown at this time, it will likely have a significant impact on the pharmaceutical industry and the pricing of our products and product candidates.
Disease Area: Infectious Diseases, Oncology, Rare Disease
Drug Type: Biologic
March 12, 2026
Whitehawk Therapeutics, Inc.
Neutral Outlook
Morristown, NJ
1-50 employees
In August 2022, Congress passed the Inflation Reduction Act of 2022 (the “Inflation Reduction Act”), which includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries
Disease Area: Oncology
Drug Type: Biologic
March 11, 2026
Verrica Pharmaceuticals Inc.
Neutral Outlook
West Chester, PA
51-200 employees
It is unclear how such challenges and the healthcare reform measures of the current administration will impact the ACA and our business.
Disease Area: Dermatology, Infectious Diseases, Oncology
Drug Type: Biologic, Small Molecule
March 11, 2026
Pliant Therapeutics/CA
Negative Outlook
South San Francisco, CA
1-50 employees
we expect these initiatives to increase pressure on drug pricing. Further, certain broader legislation that is not targeted to the healthcare industry may nonetheless adversely affect our profitability.
Disease Area: Oncology
Drug Type: Small Molecule